Serum level of vitamin D3 in vitiligo patients before and after treatment with narrow band UVB. Is there an association with treatment?

Authors

  • Golsan Kardan
  • Layegh Pouran
  • Nahidi Yalda
  • Naser Tayyebi Meibodi
  • Vida Vakili
Abstract:

Background: Vitiligo is a pigmentation disorder of the skin characterized by the loss of melanocytes through different mechanisms. Narrow band UVB (NBUVB) is a safe and effective treatment for vitiligo that acts by inducing the synthesis of cytokines involved in melanogenesis. NBUVB appears to be involved in the treatment of vitiligo by increasing the synthesis of vitamin D, which prevents the apoptosis of melanocytes; accordingly, we set out to compare the serum level of vitamin D and its variations following NBUVB treatment according to the degree of response to treatment. Methods: Thirty-eight patients with vitiligo were subject to phototherapy with NBUVB. Photographs of vitiligo lesions were taken prior to and after completing 60 phototherapy sessions. Further measured were the serum level of 25-hydroxyvitamin D3, VASI score and repigmentation rate before and after the treatment period. Finally, the relationship between the changes in serum vit D3 levels and variations of VASI score was investigated. Results: Mean serum level of vitamin D3 was 20.78 ng/ml after treatment, which is significantly more compared to the period before the treatment (15.42, P=0.001). Mean VASI score was 5.45 before the treatment, yet was reduced to 2.24 after treatment, which is a significant change (P

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Evaluation of Efficacy and Safety of Combination of Narrow Band Ultraviolet B and Topical Calcipotriol Versus Narrow Band UVB alone in the Treatment of Vitiligo

Background: Narrow band Ultraviolet B (NBUVB) has been used successfully for the treatment of vitiligo. Recently, topical calcipotriol has also been used as immunotherapy or as a part of combination therapies. The aim of this study was to compare the clinical efficacy and safety of NBUVB and NBUVB plus topical calcipotriol in the treatment of generalized vitiligo.Methods: NBUVB phototherapy was...

full text

hmb-۴۵ study before and after narrow-band (۳۱۱ nm) ultraviolet b treatment in vitiligo

conclusions the hmb-45 stain strength significantly changed after treatment in perilesional skin. results twenty-nine patients completed the study. the wilcoxon test showed a meaningful relation between hmb-45 staining before and after nb-uvb treatment in perilesional skin. we did not find a meaningful relation between hmb-45 staining before and after treatment regarding the mean age, gender, m...

full text

C-reactive protein serum level in patients with psoriasis before and after treatment with narrow-band ultraviolet B*

Background: C-reactive protein is an inflammatory biomarker and its level increases in the serum of psoriatic patients. Its level is also associated with Psoriasis Area and Severity Index score. Objective: The aim of this study was to assess the decrement of serum C-reactive protein level with narrow-band ultraviolet B (NB-UVB) therapy. Methods: C-reactive protein serum levels in psoriasis ...

full text

Treatment of vitiligo with narrow-band UVB and topical gel containing catalase and superoxide dismutase.

Narrow-band UVB has been reported to be efficacious in patients with vitiligo. The epidermis of patients with vitiligo showed reduction in the levels of catalase, in association with high levels of hydrogen peroxidase (H2O2) that is toxic for melanocytes. Based on these findings, we studied the efficacy and safety of a topical gel containing catalase and superoxide dismutase (Vitix) in combinat...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 22  issue 1

pages  1- 6

publication date 2019-03-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023